Literature DB >> 22473468

The functions and regulation of the PTEN tumour suppressor.

Min Sup Song1, Leonardo Salmena, Pier Paolo Pandolfi.   

Abstract

The importance of the physiological function of phosphatase and tensin homologue (PTEN) is illustrated by its frequent disruption in cancer. By suppressing the phosphoinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway through its lipid phosphatase activity, PTEN governs a plethora of cellular processes including survival, proliferation, energy metabolism and cellular architecture. Consequently, mechanisms regulating PTEN expression and function, including transcriptional regulation, post-transcriptional regulation by non-coding RNAs, post-translational modifications and protein-protein interactions, are all altered in cancer. The repertoire of PTEN functions has recently been expanded to include phosphatase-independent activities and crucial functions within the nucleus. Our increasing knowledge of PTEN and pathologies in which its function is altered will undoubtedly inform the rational design of novel therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22473468     DOI: 10.1038/nrm3330

Source DB:  PubMed          Journal:  Nat Rev Mol Cell Biol        ISSN: 1471-0072            Impact factor:   94.444


  160 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

Review 2.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

3.  Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.

Authors:  Hui-Kuan Lin; Zhenbang Chen; Guocan Wang; Caterina Nardella; Szu-Wei Lee; Chia-Hsin Chan; Chan-Hsin Chan; Wei-Lei Yang; Jing Wang; Ainara Egia; Keiichi I Nakayama; Carlos Cordon-Cardo; Julie Teruya-Feldstein; Pier Paolo Pandolfi
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

4.  Distinct functional outputs of PTEN signalling are controlled by dynamic association with β-arrestins.

Authors:  Evelyne Lima-Fernandes; Hervé Enslen; Emeline Camand; Larissa Kotelevets; Cédric Boularan; Lamia Achour; Alexandre Benmerah; Lucien C D Gibson; George S Baillie; Julie A Pitcher; Eric Chastre; Sandrine Etienne-Manneville; Stefano Marullo; Mark G H Scott
Journal:  EMBO J       Date:  2011-06-03       Impact factor: 11.598

5.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway.

Authors:  H Sun; R Lesche; D M Li; J Liliental; H Zhang; J Gao; N Gavrilova; B Mueller; X Liu; H Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

6.  Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7).

Authors:  Anders Sundqvist; Maria T Bengoechea-Alonso; Xin Ye; Vasyl Lukiyanchuk; Jianping Jin; J Wade Harper; Johan Ericsson
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

7.  Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia.

Authors:  Konstantinos J Mavrakis; Andrew L Wolfe; Elisa Oricchio; Teresa Palomero; Kim de Keersmaecker; Katherine McJunkin; Johannes Zuber; Taneisha James; Aly A Khan; Christina S Leslie; Joel S Parker; Patrick J Paddison; Wayne Tam; Adolfo Ferrando; Hans-Guido Wendel
Journal:  Nat Cell Biol       Date:  2010-02-28       Impact factor: 28.824

8.  Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.

Authors:  Min Sup Song; Arkaitz Carracedo; Leonardo Salmena; Su Jung Song; Ainara Egia; Marcos Malumbres; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-01-21       Impact factor: 41.582

9.  E3 ligase Nedd4 promotes axon branching by downregulating PTEN.

Authors:  Jovana Drinjakovic; Hosung Jung; Douglas S Campbell; Laure Strochlic; Asha Dwivedy; Christine E Holt
Journal:  Neuron       Date:  2010-02-11       Impact factor: 17.173

10.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

View more
  843 in total

Review 1.  Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.

Authors:  Benjamin D Hopkins; Ramon E Parsons
Journal:  Clin Cancer Res       Date:  2014-11-01       Impact factor: 12.531

2.  A PTEN-Regulated Checkpoint Controls Surface Delivery of δ Opioid Receptors.

Authors:  Daniel J Shiwarski; Alycia Tipton; Melissa D Giraldo; Brigitte F Schmidt; Michael S Gold; Amynah A Pradhan; Manojkumar A Puthenveedu
Journal:  J Neurosci       Date:  2017-03-06       Impact factor: 6.167

3.  EZH2 Methyltransferase Activity Controls Pten Expression and mTOR Signaling during Fear Memory Reconsolidation.

Authors:  Timothy J Jarome; Gabriella A Perez; Rebecca M Hauser; Katrina M Hatch; Farah D Lubin
Journal:  J Neurosci       Date:  2018-07-20       Impact factor: 6.167

Review 4.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells.

Authors:  Russell G Jones; Edward J Pearce
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

5.  Pten loss induces autocrine FGF signaling to promote skin tumorigenesis.

Authors:  Kristina Hertzler-Schaefer; Grinu Mathew; Ally-Khan Somani; Sunil Tholpady; Madhavi P Kadakia; Yiping Chen; Dan F Spandau; Xin Zhang
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

6.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Authors:  Yanlin Yu; Meng Dai; Andrew Lu; Ellen Yu; Glenn Merlino
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

7.  Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

Authors:  Anthony W Tolcher; Razelle Kurzrock; Vincente Valero; Rene Gonzalez; Rebecca S Heist; Antoinette R Tan; Julie Means-Powell; Theresa L Werner; Carlos Becerra; Chenxi Wang; Cathrine Leonowens; Shanker Kalyana-Sundaram; Joseph F Kleha; Jennifer Gauvin; Anthony M D'Amelio; Catherine Ellis; Nageatte Ibrahim; Li Yan
Journal:  Cancer Chemother Pharmacol       Date:  2020-02-15       Impact factor: 3.333

8.  Myeloid PTEN deficiency protects livers from ischemia reperfusion injury by facilitating M2 macrophage differentiation.

Authors:  Shi Yue; Jianhua Rao; Jianjun Zhu; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Ling Lu; Xuehao Wang; Yuan Zhai
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

9.  PTEN is a protein tyrosine phosphatase for IRS1.

Authors:  Yuji Shi; Junru Wang; Sarat Chandarlapaty; Justin Cross; Craig Thompson; Neal Rosen; Xuejun Jiang
Journal:  Nat Struct Mol Biol       Date:  2014-05-11       Impact factor: 15.369

10.  Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR).

Authors:  Christoph Garbers; Fabian Kuck; Samadhi Aparicio-Siegmund; Kirstin Konzak; Mareike Kessenbrock; Annika Sommerfeld; Dieter Häussinger; Philipp A Lang; Dirk Brenner; Tak W Mak; Stefan Rose-John; Frank Essmann; Klaus Schulze-Osthoff; Roland P Piekorz; Jürgen Scheller
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.